Eli Lilly and Company (LLY)
| Market Cap | 763.40B |
| Revenue (ttm) | 35.93B |
| Net Income (ttm) | 6.14B |
| Shares Out | 950.41M |
| EPS (ttm) | 6.79 |
| PE Ratio | 119.07 |
| Forward PE | 58.18 |
| Dividend | $5.20 (0.65%) |
| Ex-Dividend Date | May 15, 2024 |
| Volume | 3,526,942 |
| Open | 792.46 |
| Previous Close | 783.18 |
| Day's Range | 791.39 - 816.61 |
| 52-Week Range | 419.80 - 816.61 |
| Beta | 0.37 |
| Analysts | Strong Buy |
| Price Target | 755.50 (-5.98%) |
| Earnings Date | Apr 30, 2024 |
About LLY
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the... [Read more]
Financial Performance
In 2023, LLY's revenue was $34.12 billion, an increase of 19.56% compared to the previous year's $28.54 billion. Earnings were $5.24 billion, a decrease of -16.08%.
Financial StatementsAnalyst Forecast
According to 23 analysts, the average rating for LLY stock is "Strong Buy." The 12-month stock price forecast is $755.5, which is a decrease of -5.98% from the latest price.
News
Eli Lilly (LLY) Hits High After Diabetes Drug Approval
Eli Lilly (LLY) is higher after Chinese regulators approve diabetes drug in China. Diane King Hall discusses this as Eli Lilly's Phase 3 study of Crohn's disease treatment achieves “meaningful improve...
Eli Lilly Rises As Study Shows Omvoh Successful in Treating Crohn's Disease
Shares of Eli Lilly (LLY) were on track to close at an all-time high Tuesday as a study showed the pharmaceutical giant's current drug for ulcerative colitis also was successful in treating Crohn's di...
Healthy Returns: Eli Lilly, Novo Nordisk are competing to develop more convenient weekly insulins
The rivalry between Eli Lilly and Novo Nordisk extends beyond weight loss and diabetes drugs. Meanwhile, Uber has announced new features for caregivers.
Eli Lilly's stock on pace for record close as Crohn's disease trial hits the mark
Eli Lilly & Co. LLY shares were on pace for a record closing high Tuesday after the drugmaker released data from a late-stage Crohn's disease trial and struck a deal to develop new cancer-targeting me...
Alloy Therapeutics Announces Platform License Agreement with Lilly
BOSTON--(BUSINESS WIRE)--Alloy Therapeutics, a biotechnology ecosystem company dedicated to democratizing access to biologics drug discovery platforms and services, announced today a licensing agreeme...
More than one-half of patients with Crohn's disease treated with Lilly's mirikizumab achieved clinical remission at one year, including patients with previous biologic failure
Nearly one-half of patients on mirikizumab achieved endoscopic response at 52 weeks; most of these patients were also in clinical remission INDIANAPOLIS, May 21, 2024 /PRNewswire/ -- In Eli Lilly and ...
Aktis to collaborate with Eli Lilly on cancer therapies
Aktis Oncology said on Tuesday it will collaborate with Eli Lilly to develop cancer therapies, making it eligible for milestone payments of up to $1.1 billion and royalties on sales.
Eli Lilly's (LLY) diabetes injection Mufenda gets approval in China
Eli Lilly and Company announced on Tuesday that the National Medical Products Administration (NMPA) in China has approved the distribution of its injection Mufenda. This injection is designed to treat...
Eli Lilly's diabetes drug tirzepatide gets approval in China
Eli Lilly said on Tuesday its diabetes drug tirzepatide has received approval from Chinese regulators, setting up intensifying competition with its Danish rival Novo Nordisk in the key Asian market.
Totus Medicines Announces Strategic Multi-Target Research Collaboration with Lilly
Collaboration leverages Totus' covalent chemistry-based OmniDEL platform for the identification of small molecule drug candidates across multiple therapeutic areas Collaboration leverages Totus' coval...
Lilly's weekly insulin succeeds in late-stage studies
Eli Lilly said on Thursday that its once-weekly insulin efsitora met the main goals in two late-stage trials evaluating it in people with type 2 diabetes.
With Once-a-Week Dosing, Insulin Efsitora Alfa Delivers A1C Reduction and Safety Profile Consistent with Daily Insulin
Efsitora met the primary endpoint in both QWINT-2 and QWINT-4 with once-a-week dosing regimen for people living with type 2 diabetes Efsitora was equally safe and effective among adults naïve to insul...
Bullish On TOST & LLY
Should traders remain bullish with the current macro environment? Tom Plumb says that a good sustainable business plan, good people, disciplined allocation of capital, high return on capital, and prof...
How Are Eli Lilly's Profit Margins Trending?
Eli Lilly (NYSE: LLY) saw its net income decline by $1 billion or 16% y-o-y to $5.2 billion in 2023. This can primarily be attributed to higher acquired in-process research and development expenses (I...
UK weight-loss drug price rivalry intensifies with Pharmacy2U mark-down
Britain's Pharmacy2U said on Wednesday it had cut the prices of weight-loss medication Wegovy and Mounjaro, becoming the latest in a slew of online pharmacies and slimming clinics to do so as initial ...
Alonzo Weems to Retire as Executive Vice President of Enterprise Risk Management and Chief Ethics and Compliance Officer
INDIANAPOLIS , May 15, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that Alonzo Weems, executive vice president of enterprise risk management and chief ethics and compliance ...
Eli Lilly's and AstraZeneca's Former Head of Research Dr. Jan Lundberg Elected as a New Board Member
STOCKHOLM, SWEDEN / ACCESSWIRE / May 15, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB, a pharmaceutical company that develops candidate drugs for CNS diseases, focusing on Alzheimer...
Eli Lilly reaches settlement with spa selling Mounjaro, Zepbound knockoffs
Eli Lilly has entered into a settlement deal with a medi spa that had sold counterfeit versions of its popular diabetes drug Mounjaro and weight loss treatment Zepbound, the drugmaker said on Tuesday.
Healthy Returns: One in eight adults have taken Ozempic or other GLP-1s, survey says
A wide swath of Americans are using GLP-1s despite shortages, a survey says. Meanwhile, Google DeepMind's new AI model can predict the structure of molecules.
Is Eli Lilly Stock A Better Pick Over Amgen?
Given its better prospects, we believe Eli Lilly stock (NYSE: LLY) is a better pick than Amgen stock (NASDAQ NASDAQ : AMGN). Both stocks have been in the limelight lately, given their focus on the luc...
Healthy Returns: Eli Lilly, Novo Nordisk make progress toward boosting weight loss drug supply
Eli Lilly and Novo Nordisk are boosting supply of their weight loss drugs, while Apple Watch's heart monitoring tech was approved for use in clinical studies.
US FDA panel to discuss Eli Lilly Alzheimer's drug on June 10
Eli Lilly said on Tuesday a panel of independent U.S. FDA advisers will discuss whether the agency should approve its Alzheimer's disease drug, donanemab, on June 10.
Lilly Declares Second-Quarter 2024 Dividend
INDIANAPOLIS , May 6, 2024 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the second quarter of 2024 of $1.30 per share on outstanding common s...
Amgen stock soars on weight loss injection progress as Novo Nordisk, Eli Lilly shares slide
Amgen's update fueled concerns about potential new competition in the weight loss drug market, sending shares of Novo Nordisk and Eli Lilly lower.